logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001 See Also: Important News from Ultragenyx Pharmaceutical

Intellia Therapeutics Granted Orphan Drug Designation for NTLA-2001 Intellia Therapeutics (NTLA) announced that the U.S. FDA has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin ( ATTR ) amyloidosis. This investigational therapy is the first CRISPR therapy to...

Read More

October 21, 2021

0

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

Exelixis Press Release This press release covers a large part of Exelixis accomplishments, including important details about its pipeline products, especially, cabozantinib, in addition to new results from clinical trials. We advise Prohost subscribers to read this press release, so...

Read More

May 19, 2022

0

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Regeneron Pharmaceuticals and Sanofi Announce FDA Approval of Dupixent ® Regeneron Pharmaceuticals ( REGN ) and  Sanofi ( SNY ) announced that the U.S. FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis ( EoE ) aged...

Read More

May 23, 2022

0

Why Compugen is a Favorite Biotechnology Firm

Compugen Compugen ( CGEN ) presented its third-quarter achievements and financial results. We believe the firm is on the right track towards clinically confirming that its discovered targets, PVRIG and TIGIT when inhibited, will extend the capability of the current...

Read More

November 6, 2020

0

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals Alnylam Pharmaceuticals ( ALNY ) led the translation of RNA interference ( RNAi ) into a new class of innovative therapeutics, transforming the lives of people afflicted with rare and prevalent diseases with unmet needs. RNAi is a...

Read More

May 25, 2022

0

CRISPR Therapeutics - Professor Emmanuelle Charpentier - Gene Editing and the Future of Humanity

CRISPR Therapeutics Dr. Emmanuelle Charpentier, Co-Founder CRISPR Therapeutics ( CRSP ) announced on October 7, 2020 that Dr. Emmanuelle Charpentier has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system.  Dr. Emmanuelle Charpentier...

Read More

November 6, 2020

0

The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

United Therapeutics Approval for Tyvaso DPI™ The US FDA approved United Therapeutics ( UTHR ) product Tyvaso DPI™ (treprostinil) inhalation powder for pulmonary arterial hypertension ( PAH ) and pulmonary hypertension associated with interstitial lung disease ( ILD ) to...

Read More

May 27, 2022

0

Why Merck’s Stock Price Soared. See Also: Pulmotect Inhaled PUL-042 for Respiratory Symptoms of COVID-19 and Fujirebio Agreement with ADDF

Merck Stock Soared Great expectations for Merck ( MRK ) future growth and the future of novel treatments for patients with severe devastating and life-threatening diseases. Keytruda - Merck's cancer immunotherapy drug, has reached a milestone and molnupiravir - its...

Read More

October 28, 2021

0

About bluebird bio

bluebird bio bluebird bio ( BLUE ) financial results and business highlights for the third quarter 2020 are important to be aware of when volatility and negative analysis lack common sense. The stock selloff has been steady and progressive while...

Read More

November 10, 2020

0

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb ( BMY ) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients with moderate to severe systemic lupus erythematosus ( SLE ). The study met...

Read More

June 2, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 32
  • 33
  • 34
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy